LivaNova Reports Second Quarter 2016 Results
(Thomson Reuters ONE) -
LONDON, Aug. 03, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN)
("LivaNova" or the "Company"), a market-leading medical technology and
innovation company, today reported results for the second quarter ended June
30, 2016.
For the second quarter of 2016, worldwide sales were $321 million, an increase
of 1.3 percent on a reported basis as compared to the previous year. On a
constant-currency basis(1), sales were $319 million, an increase of 0.7 percent
over the previous year. On a U.S. Generally Accepted Accounting Principles
(GAAP) basis, second quarter 2016 diluted earnings per share were $0.18. Second
quarter 2016 adjusted(2) diluted earnings per share were $0.87.
"The second quarter was one of great progress in several areas", said André-
Michel Ballester, chief executive officer. "We were especially pleased with
early results of our Perceval launch in the U.S. We have rolled out the product
to a significant number of hospitals and physician feedback has been positive.
We are also seeing double digit growth, both in our Neuromodulation franchise
overall and importantly in our high voltage device Platinium across Europe, as
well as encouraging penetration of our low voltage device KORA 250 in Japan. At
the same time, we have seen margin improvements across the income statement and
made meaningful advances in our restructuring activities and in capturing
synergies. With accelerating top line growth in the second half of the year and
good expense discipline, we are on plan to deliver on our financial commitments
in 2016, while making exciting progress toward building sustainable long-term
growth."
__________
(1) Constant currency growth measures the change in sales between the current
and prior year periods using average exchange rates in effect during the
applicable prior year period.
(2) Adjusted measures are based on selected non-GAAP operating results and
exclude certain specified items as described later in this press release and the
attached schedules.
Second-Quarter 2016 Results
The following table highlights selected financial results(3) for the second
quarter of 2016 compared to the same period in 2015:
+---------------+-------------------+---------+---------+
| |Three Months Ended | | |
| | June 30, | |Constant |
| +---------+---------+ |Currency |
|In $ millions | 2016 | 2015 |% Change |% Change |
+---------------+---------+---------+---------+---------+
|Cardiopulmonary|$ 124.0 |$ 125.9 | (1.5 %)| (1.8 %)|
+---------------+---------+---------+---------+---------+
|Heart Valves |$ 37.1 |$ 36.4 | 1.8 % | 1.6 % |
+---------------+---------+---------+---------+---------+
|Cardiac Surgery|$ 161.1 |$ 162.3 | (0.8 %)| (1.0 %)|
+---------------+---------+---------+---------+---------+
|CRM(4) |$ 69.6 |$ 75.6 | (8.0 %)| (9.9 %)|
+---------------+---------+---------+---------+---------+
|Neuromodulation|$ 90.0 |$ 78.4 | 14.8 % | 14.9 % |
+---------------+---------+---------+---------+---------+
|Other |$ 0.4 |$ 0.7 | n/a | n/a |
+---------------+---------+---------+---------+---------+
|Total Net Sales|$ 321.0 |$ 317.1 | 1.3 % | 0.7 % |
+---------------+---------+---------+---------+---------+
* Numbers may not add due to rounding. Constant currency % change is
considered a non-GAAP metric.
For discussion purposes, all sales growth rates below reflect comparable,
constant currency growth. The difference between constant currency growth and
reported growth reflects the impact from currency in the various currencies in
which we operate.
__________
(3) See the discussion of "Financial Alignment, Combined Sales & Operating
Results, Business Unit Structure and Constant Currency" below. The sales
results presented are unaudited.
(4) Cardiac Rhythm Management.
Three months ended June 30, 2016
For the three Business Units, sales were as follows:
Cardiac Surgery
Cardiac Surgery sales, which include cardiopulmonary products and heart valves,
were $161 million, representing a 1.0 percent decrease versus the comparable
period in 2015. The increase in heart valves was more than offset by the
decline in cardiopulmonary.
Sales in cardiopulmonary products were $124 million, a decrease of 1.8 percent
compared to the second quarter of 2015. A decline in our 3T heater/cooler
devices, as a result of our import restrictions in the U.S. and the timing of
heart lung machine orders in Europe, was partially offset by a strong demand for
oxygenators, particularly in emerging markets as well as Japan and Australia.
Heart valve sales, including tissue and mechanical heart valves, were
$37 million, an increase of 1.6 percent compared to the same period the previous
year. Results were driven by strength in Perceval in both the U.S. and Europe,
which more than offset the weakness in mechanical valves, primarily in China,
and traditional tissue valves globally.
Cardiac Rhythm Management
CRM sales for the period totaled $70 million, a decrease of 9.9 percent as
compared to the second quarter of 2015. The decline in Japan was partially
offset by positive performance of our newest high-voltage device Platinium,
which was launched last November in Europe and Japan.
Neuromodulation
Neuromodulation sales were $90 million in the second quarter, an increase
of 14.9 percent over the prior year period, driven primarily by continued
adoption of our newest VNS therapy device AspireSR in the U.S. and double digit
new patient growth.
Financial Performance
On a U.S. GAAP basis, second quarter 2016 income from operations was $22 million
compared to a net loss from operations of $36 million in the first quarter of
2016. Adjusted income from operations(5) for the second quarter of 2016 was
$63 million, an increase of 23.8 percent as compared to the second quarter of
2015. This is primarily attributed to a positive mix of sales during the
quarter which improved gross margin, sound cost control, delivery of our planned
synergies and the impact of our previously announced restructuring efforts.
__________
(5) Adjusted measures exclude certain specified items as described later in this
press release and the attached schedules. Adjusted measures are based on
selected non-GAAP operating results highlights in our 2015 Annual and Fourth
Quarter Financial Results published on February 24, 2016.
2016 Projections
The Company reiterates its guidance for full year 2016.
The Company continues to expect revenue growth on a constant-currency basis in
the range of 3 to 5 percent. This includes growth in Cardiac Surgery of 3 to
5 percent, growth in Neuromodulation of 9 to 11 percent and growth in CRM of 1
to 2 percent.
The Company continues to expect adjusted gross margin in the range of 64 to
65 percent of net sales, adjusted income from operations in the range of $205 to
$230 million, and adjusted diluted earnings per share (EPS) in the range of
$2.95 to $3.15, which is based on a share count of approximately 50 million
shares on a fully diluted basis.
Webcast and Conference Call Instructions
The conference call will be available to interested parties through a live audio
webcast commencing at 8:00 AM Central time (9:00 AM Eastern Time, 2:00 pm UK
Time) and accessible through the Investor Relations section of the LivaNova
corporate website at www.livanova.com. To listen to the conference call live by
telephone, dial 877-809-8594 (if dialing from within the U.S.) or 440-996-5677
(if dialing from outside the U.S.). The conference ID is 43508560.
Within 24 hours of the webcast, a replay will be available under the "Events &
Presentations" section of the Investor Relations portion of the LivaNova
website, where it will be archived and accessible for approximately 12 months.
About LivaNova
LivaNova PLC is a global medical technology company formed by the merger of
Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and
Cyberonics Inc., a medical device company with core expertise in
neuromodulation. LivaNova transforms medical innovation into meaningful
solutions for the benefit of patients, healthcare professionals, and healthcare
systems. The Company employs approximately 4,600 employees worldwide and is
headquartered in London, U.K. With a presence in more than 100 countries,
LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm
Management, and Neuromodulation, with operating headquarters in Clamart
(France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and is admitted to the standard listing segment of
the Official List of the UK's Financial Conduct Authority and to trading on the
London Stock Exchange (LSE) under the ticker symbol "LIVN".
Financial Alignment, Combined Sales & Operating Results, Business Unit Structure
and Constant Currency
Cyberonics, the predecessor company to LivaNova, previously reported on a 52/53
week fiscal year calendar ending in April. With the formal change in the fiscal
calendar to a fiscal year ended December 31, the historical Neuromodulation
business unit sales have been aligned to correspond as closely as possible to
calendar quarters.
Although LivaNova was a shell company with no business operations until the
closing date of the merger on October 19, 2015, the sales results disclosed for
periods up to and beyond that date are being provided on a combined basis, a
non-GAAP formulation that combines the results of legacy Sorin and Cyberonics
for the periods completed prior to the merger and periods that include results
both before and after the closing of the merger. The Company believes that
presenting the results of Sorin and Cyberonics in such a manner offers a
meaningful representation to investors of the combined company's sales for these
periods.
Non-GAAP operating results, unaudited, have been included for each of the
quarters ended March 31, 2015, June 30, 2015, September 30, 2015 and December
31, 2015 and for the year ended December 31, 2015. These results have been
prepared by management and adjusted for non-GAAP items as if the merger had
occurred on January 1, 2015 but should not be considered as an alternative to
Proforma Income Statements to be provided in accordance with SEC filings.
Certain adjustments to legacy Sorin operating results have occurred in order to
present the results in US dollars and to align these results as closely as
possible to the presentation of LivaNova financial results. Company management
uses these measurements as aids in monitoring the Company's ongoing financial
performance from quarter to quarter and year to year on a regular basis and for
benchmarking against other medical technology companies. Management believes
that the presentation of these results provides a meaningful representation of
the combined company's operating results for the periods presented.
The sales and operating results for legacy Cyberonics for the quarters ended
March 31, June 30 and September 30 were aligned to provide comparative
information. The actual periods ended on March 27, June 26 and September 25
respectively.
LivaNova (as the successor to Sorin and Cyberonics on a combined basis) operates
under a Business Unit structure with Cardiac Surgery, CRM and Neuromodulation
accounting for substantially all of the sales during the periods referred to
herein. The combined company also operates a New Ventures group, dedicated to
developing new technologies, particularly in the areas of heart failure, sleep
apnea and percutaneous mitral valve.
Use of Non-GAAP Financial Measures
In this press release, management has disclosed financial measurements that
present financial information not necessarily in accordance with Generally
Accepted Accounting Principles (GAAP). Company management uses these
measurements as aids in monitoring the Company's ongoing financial performance
from quarter to quarter and year to year on a regular basis and for benchmarking
against other medical technology companies. Non-GAAP financial measures used by
the Company may be calculated differently from, and therefore may not be
comparable to, similarly-titled measures used by other companies. These non-
GAAP financial measures should be considered along with, but not as alternatives
to, the operating performance measure as prescribed by GAAP.
Unless otherwise noted, all sales growth rates in this release reflect
comparable, constant currency growth. Management believes that referring to
comparable, constant currency growth is the most useful way to evaluate the
sales performance of LivaNova and to compare the sales performance of current
periods to prior periods on a consistent basis. Constant currency growth, a non-
GAAP financial measure, measures the change in sales between current and prior
year periods using average exchange rates in effect during the applicable prior
year period.
Safe harbor statement
This press release contains forward-looking statements within the meaning of
Section 27A of the United States Securities Act of 1933, as amended, and Section
21E of the United States Securities Exchange Act of 1934, as amended. Forward-
looking statements are not historical facts but are based on certain assumptions
of management and describe the Company's future plans, strategies and
expectations. Forward-looking statements can generally be identified by the use
of forward-looking terminology, including, but not limited to, "may," "could,"
"seek," "guidance," "predict," "potential," "likely," "believe," "will,"
"expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations
of these terms and similar expressions, or the negative of these terms or
similar expressions. Forward-looking statements contained in this press release
are based on information presently available to LivaNova and assumptions that
the Company believes to be reasonable, but are inherently uncertain. As a
result, our actual results, performance or achievements may differ materially
from those expressed or implied by these forward-looking statements, which are
not guarantees of future performance and involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond the Company's
control. Investors are cautioned that all such statements involve risks and
uncertainties, including without limitation, statements concerning developing
novel opportunities in neuromodulation, heart failure, sleep apnea and
percutaneous mitral valve, creating new innovative solutions that benefit
patients, healthcare professionals, and healthcare systems, and building
significant shareholder value. Important factors that may cause actual results
to differ include, but are not limited to: (i) risks that the legacy businesses
of Cyberonics, Inc. and Sorin S.p.A. (together, the "combined companies") will
not be integrated successfully or that the combined companies will not realize
estimated cost savings, value of certain tax assets, synergies and growth, or
that such benefits may take longer to realize than expected; (ii) the inability
of LivaNova to meet expectations regarding the timing, completion and accounting
of tax treatments; (iii) risks relating to unanticipated costs of integration,
including operating costs, customer loss or business disruption being greater
than expected; (iv) our organizational and governance structure; (v) reductions
in customer spending, a slowdown in customer payments and changes in customer
demand for products and services; (vi) unanticipated changes relating to
competitive factors in the industries in which LivaNova operates; (vii) the
ability to hire and retain key personnel; (viii) the ability to attract new
customers and retain existing customers in the manner anticipated; (ix) the
reliance on and integration of information technology systems; (x) changes in
legislation or governmental regulations affecting LivaNova; (xi) international,
national or local economic, social or political conditions that could adversely
affect LivaNova, its partners or its customers; (xii) conditions in the credit
markets; (xiii) business and other financial risks inherent to the industries in
which LivaNova operates; (xiv) risks associated with assumptions made in
connection with critical accounting estimates and legal proceedings; (xv)
LivaNova's international operations, which are subject to the risks of currency
fluctuations and foreign exchange controls; (xvi) and the potential of
international unrest, economic downturn or effects of currencies, tax
assessments, tax adjustments, anticipated tax rates, raw material costs or
availability, benefit or retirement plan costs, or other regulatory compliance
costs. The foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and uncertainties that affect
the Company's business, including those described in the "Risk Factors" section
of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K, the Registration Statement on Form S-4 and other documents filed
from time to time with the United States Securities and Exchange Commission by
LivaNova. LivaNova does not give any assurance (1) that LivaNova will achieve
its expectations, or (2) concerning any result or the timing thereof, in each
case, with respect to any regulatory action, administrative proceedings,
government investigations, litigation, warning letters, consent decree, cost
reductions, business strategies, earnings or revenue trends or future financial
results.
All information in this press release is as of the date of its release. The
Company does not undertake or assume any obligation to update publicly any of
the forward-looking statements in this press release to reflect actual results,
new information or future events, changes in assumptions or changes in other
factors affecting forward-looking statements, except to the extent required by
applicable law. If we update one or more forward-looking statements, no
inference should be drawn that we will make additional updates with respect to
those or other forward-looking statements. We caution you not to place undue
reliance on any forward-looking statements, which are made only as of the date
of this press release.
For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications(at)livanova.com
LIVANOVA PLC
QUARTERLY SALES TREND BY BUSINESS UNIT
U.S. dollar in millions, CONSTANT CURRENCY
1Q15 2Q15 3Q15 4Q15 FY15 1Q16 2Q16 2Q16 vs. 2Q15
--------- --------- --------- --------- ----------- --------- --------- ------------------
Net sales
Cardio $ 113.4 $ 123.6
Pulmonary $ 107.5 $ 125.9 $ 113.0 $ 130.0 $ 476.4 (1.8 %)
Heart Valves 34.7 36.4 34.2 34.9 140.2 33.4 37.0 1.6 %
--------- --------- --------- --------- ----------- --------- --------- ------------------
Cardiac Surgery 146.8 160.7
Total 142.2 162.3 147.2 164.9 616.6 (1.0 %)
CRM 70.4 75.6 53.9 60.7 260.5 62.9 68.1 (9.9 %)
Neuromodulation 70.1 78.4 84.3 91.5 324.3 81.6 90.1 14.9 %
Other 0.7 0.7 0.8 0.9 3.2 0.5 0.4 n/a
--------- --------- --------- --------- ----------- --------- --------- ------------------
Total $ 283.4 $ 317.1 $ 286.1 $ 318.0 $ 1,204.6 $ 291.8 $ 319.3 0.7 %
--------- --------- --------- --------- ----------- --------- --------- ------------------
QUARTERLY SALES TREND BY BUSINESS UNIT
U.S. dollar in millions, REPORTED
1Q16 2Q16 2Q16 vs.
1Q15 2Q15 3Q15 4Q15 FY15 2Q15
--------- --------- --------- --------- ----------- --------- --------- --------------
Net sales
Cardio $ 110.9 $ 124.0
Pulmonary $ 107.5 $ 125.9 $ 113.0 $ 130.0 $ 476.4 (1.5 %)
Heart Valves 34.7 36.4 34.2 34.9 140.2 32.5 37.1 1.8 %
--------- --------- --------- --------- ----------- --------- --------- --------------
Cardiac Surgery 143.4 161.1
Total 142.2 162.3 147.2 164.9 616.6 (0.8 %)
CRM 70.4 75.6 53.9 60.7 260.5 61.7 69.6 (8.0 %)
Neuromodulation 70.1 78.4 84.3 91.5 324.3 81.4 90.0 14.8 %
Other 0.7 0.7 0.8 0.9 3.2 0.4 0.4 n/a
--------- --------- --------- --------- ----------- --------- --------- --------------
Total $ 283.4 $ 317.1 $ 286.1 $ 318.0 $ 1,204.6 $ 287.0 $ 321.0 1.3 %
--------- --------- --------- --------- ----------- --------- --------- --------------
*Numbers may not add due to rounding.
LIVANOVA PLC
QUARTERLY SALES TREND BY REGION
U.S. dollar in millions, CONSTANT CURRENCY
1Q16 2Q16 2Q16 vs.
1Q15 2Q15 3Q15 4Q15 FY15 2Q15
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Cardio
Pulmonary
US $ 32.9 $ 43.0 $ 39.8 $ 45.9 $ 161.7 $ 34.5 $ 39.2 (8.7 %)
Europe 33.6 37.1 31.7 35.6 137.9 32.4 34.6 (6.7 %)
Rest of World 41.0 45.9 41.5 48.5 176.9 46.6 49.8 8.7 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 107.5 125.9 113.0 130.0 476.4 113.4 123.6 (1.8 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Heart Valve
US 6.7 6.7 6.1 5.8 25.2 6.5 7.1 6.2 %
Europe 12.8 13.0 10.3 10.9 46.9 11.7 12.4 (4.5 %)
Rest of World 15.2 16.8 17.8 18.2 68.1 15.2 17.6 4.5 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 34.7 36.4 34.2 34.9 140.2 33.4 37.0 1.6 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Cardiac Surgery
US 39.6 49.6 45.9 51.7 186.9 40.9 46.3 (6.7 %)
Europe 46.3 50.0 41.9 46.5 184.8 44.0 47.0 (6.1 %)
Rest of World 56.2 62.7 59.3 66.7 245.0 61.8 67.4 7.5 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 142.2 162.3 147.2 164.9 616.6 146.8 160.7 (1.0 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
CRM
US 4.5 3.9 3.9 3.1 15.5 3.0 2.3 (41.0 %)
Europe 51.0 52.3 44.8 50.5 198.6 51.2 53.5 2.4 %
Rest of World 14.9 19.4 5.1 7.0 46.4 8.7 12.3 (36.7 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 70.4 75.6 53.9 60.7 260.5 62.9 68.1 (9.9 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Neuromodulation
US 57.5 63.6 70.9 76.8 268.8 70.2 75.8 19.2 %
Europe 8.7 8.9 8.4 9.2 35.2 6.6 9.4 6.3 %
Rest of World 3.9 6.0 4.9 5.5 20.3 4.8 4.9 (18.2 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 70.1 78.4 84.3 91.5 324.3 81.6 90.1 14.9 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Other
US 0.0 0.0 0.0 0.0 0.0 0.0 0.0 n/a
Europe 0.0 0.0 0.0 0.2 0.3 0.1 0.1 n/a
Rest of World 0.7 0.7 0.8 0.7 2.9 0.5 0.3 n/a
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 0.7 0.7 0.8 0.9 3.2 0.5 0.4 n/a
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total
US 101.6 117.1 120.8 131.6 471.2 114.1 124.4 6.2 %
Europe 106.1 111.2 95.2 106.4 418.8 101.9 110.0 (1.1 %)
Rest of World 75.7 88.8 70.2 79.9 314.6 75.8 84.9 (4.4 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total $ 283.4 $ 317.1 $ 286.1 $ 318.0 $ 1,204.6 $ 291.8 $ 319.3 $ 0.7 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
*Numbers may not add due to rounding.
LIVANOVA PLC
QUARTERLY SALES TREND BY REGION
U.S. dollar in millions, REPORTED
1Q16 2Q16 2Q16 vs.
1Q15 2Q15 3Q15 4Q15 FY15 2Q15
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Cardio
Pulmonary
US $ 32.9 $ 43.0 $ 39.8 $ 45.9 $ 161.7 $ 34.5 $ 39.2 (8.7 %)
Europe 33.6 37.1 31.7 35.6 137.9 31.5 34.9 (5.9 %)
Rest of World 41.0 45.9 41.5 48.5 176.9 45.0 49.9 8.7 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 107.5 125.9 113.0 130.0 476.4 110.9 124.0 (1.5 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Heart Valve
US 6.7 6.7 6.1 5.8 25.2 6.5 7.1 6.2 %
Europe 12.8 13.0 10.3 10.9 46.9 11.4 12.5 (3.7 %)
Rest of World 15.2 16.8 17.8 18.2 68.1 14.7 17.5 4.3 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 34.7 36.4 34.2 34.9 140.2 32.5 37.1 1.8 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Cardiac Surgery
US 39.6 49.6 45.9 51.7 186.9 40.9 46.3 (6.7 %)
Europe 46.3 50.0 41.9 46.5 184.8 42.9 47.4 (5.3 %)
Rest of World 56.2 62.7 59.3 66.7 245.0 59.7 67.4 7.5 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 142.2 162.3 147.2 164.9 616.6 143.4 161.1 (0.8 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
CRM
US 4.5 3.9 3.9 3.1 15.5 3.0 2.3 (41.0 %)
Europe 51.0 52.3 44.8 50.5 198.6 50.0 54.4 4.1 %
Rest of World 14.9 19.4 5.1 7.0 46.4 8.7 12.9 (33.7 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 70.4 75.6 53.9 60.7 260.5 61.7 69.6 (8.0 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Neuromodulation
US 57.5 63.6 70.9 76.8 268.8 70.2 75.8 19.2 %
Europe 8.7 8.9 8.4 9.2 35.2 6.4 9.4 5.6 %
Rest of World 3.9 6.0 4.9 5.5 20.3 4.8 4.9 (18.4 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 70.1 78.4 84.3 91.5 324.3 81.4 90.0 14.8
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Other
US 0.0 0.0 0.0 0.0 0.0 0.0 0.0 n/a
Europe 0.0 0.0 0.0 0.2 0.3 0.1 0.1 n/a
Rest of World 0.7 0.7 0.8 0.7 2.9 0.4 0.3 n/a
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total 0.7 0.7 0.8 0.9 3.2 0.4 0.4 n/a
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total
US 101.6 117.1 120.8 131.6 471.2 114.1 124.4 6.2 %
Europe 106.1 111.2 95.2 106.4 418.8 99.3 111.2 0.0 %
Rest of World 75.7 88.8 70.2 79.9 314.6 73.5 85.4 (3.7 %)
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
Total $ 283.4 $ 317.1 $ 286.1 $ 318.0 $ 1,204.6 $ 287.0 $ 321.0 $ 1.3 %
----------- ----------- ----------- ----------- ------------- ----------- ----------- ---------------
*Numbers may not add due to rounding.
LIVANOVA PLC
QUARTERLY SALES
U.S. dollar in millions
Three Months Ended
June 30, 2016
-----------------------
% Change % Change
at at
Actual Constant
Currency Currency
2016 2015 Rates Rates
----------- ----------- ---------------- ---------------
Cardio Pulmonary
US $ 39.2 $ 43.0 (8.7 %) (8.7 %)
Europe 34.9 37.1 (5.9 %) (6.7 %)
Rest of World 49.9 45.9 8.7 % 8.7 %
----------- -----------
Total 124.0 125.9 (1.5 %) (1.8 %)
----------- -----------
Heart Valve
US 7.1 6.7 6.2 % 6.2 %
Europe 12.5 13.0 (3.7 %) (4.5 %)
Rest of World 17.5 16.8 4.3 % 4.5 %
----------- -----------
Total 37.1 36.4 1.8 % 1.6 %
----------- -----------
Cardiac Surgery
US 46.3 49.6 (6.7 %) (6.7 %)
Europe 47.4 50.0 (5.3 %) (6.1 %)
Rest of World 67.4 62.7 7.5 % 7.5 %
----------- -----------
Total 161.1 162.3 (0.8 %) (1.0 %)
----------- -----------
CRM
US 2.3 3.9 (41.0 %) (41.0 %)
Europe 54.4 52.3 4.1 % 2.4 %
Rest of World 12.9 19.4 (33.7 %) (36.7 %)
----------- -----------
Total 69.6 75.6 (8.0 %) (9.9 %)
----------- -----------
Neuromodulation
US 75.8 63.6 19.2 % 19.2 %
Europe 9.4 8.9 5.6 % 6.3 %
Rest of World 4.9 6.0 (18.4 %) (18.2 %)
----------- -----------
Total 90.0 78.4 14.8 % 14.9 %
----------- -----------
Other
US 0.0 0.0 n/a n/a
Europe 0.1 0.0 n/a n/a
Rest of World 0.3 0.7 n/a n/a
----------- -----------
Total 0.4 0.7 n/a n/a
----------- -----------
Total
US 124.4 117.1 6.2 % 6.2 %
Europe 111.2 111.2 0.0 % (1.1 %)
Rest of World 85.4 88.8 (3.7 %) (4.4 %)
----------- -----------
Total $ 321.0 $ 317.1 1.3 % 0.7 %
----------- -----------
*Numbers may not add due to rounding.
LIVANOVA PLC
QUARTERLY SALES
U.S. dollar in millions
Six Months Ended June
30, 2016
-----------------------
% Change % Change
at at
Actual Constant
Currency Currency
2016 2015 Rates Rates
----------- ----------- ---------------- ---------------
Cardio Pulmonary
US $ 73.7 $ 75.9 (2.9 %) (2.9 %)
Europe 66.4 70.7 (6.1 %) (5.3 %)
Rest of World 94.8 86.9 9.2 % 11.0 %
----------- -----------
Total 234.9 233.4 0.6 % 1.6 %
----------- -----------
Heart Valve
US 13.5 13.4 1.3 % 1.3 %
Europe 23.9 25.7 (7.2 %) (6.4 %)
Rest of World 32.2 32.0 0.6 % 2.4 %
----------- -----------
Total 69.6 71.1 (2.1 %) (1.0 %)
----------- -----------
Cardiac Surgery
US 87.2 89.3 (2.3 %) (2.3 %)
Europe 90.2 96.4 (6.4 %) (5.6 %)
Rest of World 127.0 118.9 6.8 % 8.7 %
----------- -----------
Total 304.5 304.5 (0.0 %) 1.0 %
----------- -----------
CRM
US 5.3 8.5 (37.5 %) (37.5 %)
Europe 104.4 103.2 1.1 % 1.5 %
Rest of World 21.6 34.3 (37.0 %) (38.8 %)
----------- -----------
Total 131.3 146.0 (10.1 %) (10.2 %)
----------- -----------
Neuromodulation
US 146.0 121.0 20.6 % 20.6 %
Europe 15.7 17.6 (10.7 %) (9.0 %)
Rest of World 9.6 9.9 (2.7 %) (2.3 %)
----------- -----------
Total 171.4 148.6 15.4 % 15.6 %
----------- -----------
Other
US 0.0 0.0 n/a n/a
Europe 0.2 0.0 n/a n/a
Rest of World 0.7 1.4 n/a n/a
----------- -----------
Total 0.8 1.4 n/a n/a
----------- -----------
Total
US 238.5 218.8 9.0 % 9.0 %
Europe 210.5 217.2 (3.1 %) (2.4 %)
Rest of World 159.0 164.5 (3.4 %) (2.3 %)
----------- -----------
Total $ 608.0 $ 600.5 1.3 % 1.8 %
----------- -----------
*The sales results presented are unaudited. Numbers may not add due to
rounding.
LIVANOVA PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
U.S. dollars in millions, except share and per share amounts
Three
Months
Ended June
30,
2016
---------------------
Net sales $ 321.0
Cost of sales 130.7
---------------------
Gross profit 190.4
---------------------
Operating expenses
Selling, general and administrative 120.2
Research and development 30.2
Merger and integration expense 6.2
Restructuring expense 4.2
Amortization of intangible assets 6.3
Litigation related expenses 1.3
---------------------
Total operating expenses 168.4
---------------------
Income (loss) from operations 22.0
---------------------
Other Income
Interest income (expense) 1.7
Foreign exchange and other - (gain) loss (0.6 )
---------------------
Income (loss) before income taxes 20.9
---------------------
Loss from equity method investments 3.5
Income tax expense (benefit) 8.4
---------------------
Net (loss) income $ 9.0
---------------------
Earnings (loss) per common share:
Basic $ 0.18
Diluted $ 0.18
Weighted average common shares outstanding (in
millions)
Basic 49.1
Diluted 49.2
Adjusted Gross Profit((1)) $ 209.0
Adjusted SG&A((1)) 116.3
Adjusted R&D((1)) 30.0
Adjusted Income from Operations((1)) 62.8
Adjusted Net Income((1)) 43.0
Adjusted Diluted Earnings Per Share((1)) $ 0.87
Statistics (as a % of net sales, except for
income tax rate)
GAAP
Three
Months Adjusted((1)) Three
Ended Months Ended
June 30, June 30,
---------- --------------------------
2016 2016 2015
---------- --------------------------
Gross Profit 59.3 % 65.1 % 62.8 %
SG&A 37.4 % 36.2 % 35.6 %
R&D 9.4 % 9.3 % 11.2 %
Income from Operations (loss) 6.8 % 19.5 % 16.0 %
Net Income (loss) 2.8 % 13.4 % n/a
Income Tax Rate 40.3 % 25.9 % n/a
((1)Adjusted financial measures are Non-GAAP measures and exclude specified
items as described and reconciled to compare GAAP financial measures in the
Reconciliation of GAAP to non-GAAP Financial Measures contained in the press
release.)
*Numbers may not add due to rounding. n/a is not applicable; there is no
applicable adjusted net income or tax rate reported for 2Q15.
LIVANOVA PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
U.S. dollars in millions, except share and per share amounts
Six Months
Ended June
30,
2016
--------------------
Net sales $ 608.0
Cost of sales 254.2
--------------------
Gross profit 353.8
--------------------
Operating expenses
Selling, general and administrative 235.8
Research and development 61.9
Merger and integration expense 13.0
Restructuring expense 32.8
Amortization of intangible assets 22.2
Litigation related expenses 2.3
--------------------
Total operating expenses 367.9
--------------------
Income (loss) from operations (14.2 )
--------------------
Other Income
Interest income (expense) 2.6
Foreign exchange and other - (gain) loss 1.2
--------------------
Income (loss) before income taxes (18.0 )
--------------------
Loss from equity method investments 6.3
Income tax expense (benefit) 7.2
--------------------
Net (loss) income $ (31.4 )
--------------------
Earnings (loss) per common share:
Basic $ (0.64 )
Diluted $ (0.64 )
Weighted average common shares outstanding (in
millions)
Basic 49.0
Diluted 49.0
Adjusted Gross Profit((1)) $ 394.1
Adjusted SG&A((1)) 226.5
Adjusted R&D((1)) 61.3
Adjusted Income (loss) from Operations((1)) 106.3
Adjusted Net Income (loss)( (1)) 69.5
Adjusted Diluted Earnings Per Share((1)) $ 1.42
Statistics (as a % of net sales, except for
income tax rate)
GAAP Six
Months Adjusted((1)) Six
Ended Months Ended
June 30, June 30,
------------ ----------------------
2016 2016 2015
------------ ----------------------
Gross Profit 58.2 % 64.8 % 63.4 %
SG&A 38.8 % 37.3 % 36.8 %
R&D 10.2 % 10.1 % 12.0 %
Income from Operations (loss) (2.3 %) 17.5 % 14.6 %
Net Income (loss) (5.2 %) 11.4 % n/a
Income Tax Rate (39.8 %) 26.8 % n/a
((1)Adjusted financial measures are Non-GAAP measures and exclude specified
items as described and reconciled to compare GAAP financial measures in the
Reconciliation of GAAP to non-GAAP Financial Measures contained in the press
release.)
*Numbers may not add due to rounding. n/a is not applicable; there is no
applicable adjusted net income or tax rate reported for 2Q15.
LIVANOVA PLC AND SUBSIDIARIES
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
U.S. dollars in millions, except share and per share amounts
Three Months Income
Ended June Sales Gross From Net Diluted
30, 2016 Profit Operations Income EPS
------------------- ------- ------------ ---------------- ------------ --------------
GAAP Financial 321.0
Measures $ $ 190.4 $ 22.0 $ 9.0 $ 0.18
Specified Items
Merger and
integration
expense((A)) 6.2 5.2 0.11
Restructuring
expense((B)) 4.2 3.7 0.07
Amortization of
intangible
assets((C)) 4.6 10.9 8.7 0.18
Other
income/expenses &
litigation((D)) 1.5 (0.3 ) (0.01 )
Impact of
inventory step-
up((E)) 13.7 13.7 9.4 0.19
Equity
compensation((F)) 0.3 4.2 3.5 0.07
Certain tax
adjustments((G)) 3.8 0.08
--------- ------------ ---------------- ------------ --------------
Adjusted 321.0
financial
measures $ $ 209.0 $ 62.8 $ 43.0 $ 0.87
--------- ------------ ---------------- ------------ --------------
*Numbers may not add due to rounding.
GAAP results for the three months ended June 30, 2016 include:
((A))Expenses related to merger and integration activities; includes $0.3 of
equity compensation based on the merger.
((B))Restructuring expenses, including CRM restructuring announced March
10, 2016 and severance related to corporate and shared service synergies.
((C))Includes amortization associated with final purchase price accounting.
((D))Includes a $4.7 million reimbursement of damages related to 2012
earthquake that happened in Mirandola (Italy), a $5.0 million write-off of
receivables in relation to Greece distributors, and a $1.3 million expense
associated with litigation related to 3T heater/cooler.
((E))Includes the amortization of inventory step-up associated with final
purchase price accounting.
((F))Includes $3.6 million related to SG&A and $0.2 million related to R&D.
((G))Relates to the impact of restrucring initiatives and IP migration.
Please see "Use of Non-GAAP Financial Measures" above
Income
Six Months Ended Sales Gross From Net Diluted
June 30, 2016 Profit Operations Income EPS
------------------- --------- ------------ ---------------- --------------- --------------
GAAP Financial 608.0
Measures $ $ 353.8 $ (14.2 ) $ (31.4 ) $ (0.64 )
Specified Items
Merger and
integration
expense((A)) 13.0 11.1 0.23
Restructuring
expense((B)) 32.8 30.5 0.62
Amortization of
intangible
assets((C)) 4.6 26.8 19.6 0.40
Other
income/expenses &
litigation((D)) 2.5 0.6 0.01
Impact of
inventory step-
up((E)) 35.0 35.0 24.0 0.49
Equity
compensation((F)) 0.7 10.3 8.9 0.18
Certain tax
adjustments((G)) 6.2 0.13
--------- ------------ ---------------- --------------- --------------
Adjusted 608.0
financial
measures $ $ 394.1 $ 106.3 $ 69.5 $ 1.42
--------- ------------ ---------------- --------------- --------------
*Numbers may not add due to rounding.
GAAP results for the three months ended June 30, 2016 include:
((A))Expenses related to merger and integration activities; includes $0.5 of
equity compensation based on merger.
((B))Restructuring expenses, including CRM restructuring announced March
10, 2016 and severance related to corporate and shared service synergies.
((C))Includes amortization associated with final purchase price accounting.
((D))Includes a $4.7 million reimbursement of damages related to 2012
earthquake that happened in Mirandola (Italy), a $ 5.0 million write-off of
receivables in relation to Greece distributors, and a $2.3 million expense
primarily associated with litigation related to 3T heater/cooler.
((E))Includes the amortization of inventory step-up associated with final
purchase price accounting.
((F))Includes $9.0 million related to SG&A and $0.6 million related to R&D.
((G))Relates to the impact of restrucring initiatives and IP migration.
Please see "Use of Non-GAAP Financial Measures" above
LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. dollars in millions
June 30, 2016 December 31, 2015
------------------- --------------------
(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents $ 63.9 $ 112.6
Short-term investments 7.0 7.0
Accounts receivable, net 299.6 272.4
Inventories 192.7 212.5
Prepaid taxes 47.3 42.4
Prepaid expenses and other current
assets 51.8 26.6
------------------- --------------------
Total Current Assets 662.3 673.4
------------------- --------------------
Property, plant and equipment, net 245.0 244.6
Goodwill 731.2 745.4
Intangible assets, net 659.3 658.9
Investments 72.2 77.5
Deferred tax assets, net 8.3 153.5
Other assets 146.5 5.4
------------------- --------------------
Total Assets $ 2,524.9 $ 2,558.7
------------------- --------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Current debt obligations $ 68.9 $ 82.5
Accounts payable 121.2 109.6
Accrued liabilities 63.2 63.0
Income taxes payable 20.1 26.7
Accrued employee compensation and
related benefits liability 70.5 77.3
----------------- --------------------
Total Current Liabilities 343.9 359.1
----------------- --------------------
Long-term debt obligations 83.3 91.8
Long-term deferred income taxes
liability 212.4 235.5
Long-term employee compensation and
related benefits liability 31.9 31.1
Other long-term liabilities 29.6 29.7
------------------- --------------------
Total Liabilities 701.0 747.3
------------------- --------------------
Total Stockholders' Equity 1,823.8 1,811.5
--
Datum: 03.08.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 487083
Anzahl Zeichen: 65598
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 229 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"LivaNova Reports Second Quarter 2016 Results"
steht unter der journalistisch-redaktionellen Verantwortung von
LivaNova PLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
